Summary
Objective
Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement of anthropometric and metabolic parameters. The aim of the study was to evaluate the effects of DR-HC on insulin secretion and sensitivity and cardio metabolic risk, indirectly expressed by the visceral adiposity index (VAI).
Design and patients
Retrospective analysis of 49 patients, 13 with primary and 36 with secondary adrenal insufficiency (AI) respectively, on conventional glucocorticoid treatment at baseline and switched to DR-HC for 36 months.
Overall, 24 patients had AI-pre-diabetes (impaired fasting glucose, impaired glucose tolerance and the combination) and 25 had AI-normal glucose tolerance (NGT).
Measurements
Clinical and metabolic parameters, including VAI, insulin secretion and sensitivity indexes [fasting insulinemia, AUC2h insulinemia, oral disposition index (Dio) and ISI-Matsuda] were evaluated.
Results
In patients with AI-NGT and AI-pre-diabetes a significant decrease in BMI (p= 0.017 and p< 0.001), waist circumference (p= 0.008 and p< 0.001), HbA1c (p= 0.034 and p= 0.001) and a significant increase in HDL-C (p= 0.036 and p= 0.043) were respectively observed.
In addition, in pre-diabetic patients only we found a significant decrease in insulinemia (p= 0.014), AUC2h insulinemia (p= 0.038) and VAI (p= 0.001), in concomitance with a significant increase in DIo (p= 0.041) and ISI-Matsuda (p= 0.038).
Conclusions
Long-term DR-HC therapy is associated with an improvement in insulin secretion and sensitivity in patients with pre-diabetes. However, all patients appear to benefit from the treatment in terms of improvement of metabolic and anthropometric parameters. Larger studies are required to confirm our preliminary data.
This article is protected by copyright. All rights reserved.
http://ift.tt/2BrNMqs
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου